EJNMMI Reports

Table 3 Agreement between PET/CT (number of positive joints) and clinical parameters

From: ¹⁸F- FDG PET/CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximab

Joints	Baseline: Kappa (CI 95%)		W16 Kappa (CI 95%)
Joints	Tenderness	Swelling	Tenderness	Swelling
Knees	0.14 (−0.19, 0.47)	0.29 (−0.04, 0.61)	0.16 (0.00, 0.33)	0.04 (−0.25, 0.32)
Wrists	0.06 (−0.25, 0.37)	0.05 (−0.31, 0.41)	−0.16 (−0.47, 0.15)	−0.24 (−0.54, 0.06)
MCPs	0.04 (−0.10, 0.19)	0.54 (0.40, 0.68)	0.16 (0.01, 0.32)	0.38 (0.22, 0.54)
PIPs	0.29 (0.14, 0.45)	0.43 (0.29, 0.57)	0.10 (0.00, 0.21)	0.36 (0.21, 0.51)
Global	0.19 (0.09, 0.28)	0.43 (0.34, 0.53)	0.12 (0.04, 0.21)	0.29 (0.19, 0.38)

Back to article page